Oncotelic Therapeutics Inc. (OTCQB: OTLC) has launched an AI-powered manufacturing services platform designed to address a critical challenge in the biotechnology industry: the lack of access to full Good Manufacturing Practice (GMP) infrastructure for emerging companies. The platform integrates Oncotelic’s proprietary PDAOAI architecture with digital manufacturing technologies and intelligent robotics developed in collaboration with TechForce Robotics, the company’s strategic robotics and automation partner.
Unlike many AI applications in biotech that focus solely on drug discovery, Oncotelic’s platform targets manufacturing workflows, which are often the bottleneck in moving a therapy from development to commercialization. The platform is already deployed at Oncotelic’s GMP-certified SAPU manufacturing facility, where it supports the company’s own clinical pipeline. This dual-use approach adds a second layer to Oncotelic’s business model: the company remains a clinical-stage biotech, but the AI-GMP platform could extend its role into enabling infrastructure for other drug developers.
If adopted commercially, the platform could create a services-based revenue opportunity for Oncotelic while strengthening its internal development engine. The integration with TechForce Robotics’ automation capabilities reflects a broader industry shift toward intelligent manufacturing systems that reduce manual workload and tighten compliance discipline. This is particularly important as regulatory requirements for GMP become increasingly stringent, and as the industry faces pressures to accelerate time-to-market for new therapies.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company’s CEO, Dr. Vuong Trieu, has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, Oncotelic licenses and codevelops select drug candidates through joint ventures, including a 45% ownership in GMP Bio, which is advancing its own pipeline of drug candidates that complement Oncotelic’s strategic position in oncology and rare disease therapeutics.
The launch of the AI-GMP platform could have significant implications for the biotech industry. For emerging biotech companies, the platform offers a way to access state-of-the-art manufacturing capabilities without the massive capital expenditure required to build their own GMP facilities. This could lower barriers to entry and enable smaller firms to bring therapies to market more efficiently. For Oncotelic, the platform represents a potential new revenue stream and a way to leverage its existing infrastructure and expertise. The collaboration with TechForce Robotics also positions Oncotelic at the forefront of the trend toward automation and AI in biopharmaceutical manufacturing.
For more information about Oncotelic Therapeutics, visit the company’s newsroom at https://ibn.fm/OTLC. The full article discussing the platform is available at https://ibn.fm/zB53J.
